Garin Etienne, Denizot Benoit, Roux Jérôme, Noiret Nicolas, Lepareur Nicolas, Moreau Myriam, Mesba Abiba, Laurent Jean-François, Herry Jean-Yves, Bourguet Patrick, Benoit Jean-Pierre, Lejeune Jean-Jacques
UPRES EA 3890/Nuclear Medicine Service, Centre Eugène Marquis, rue de la Bataille Flanders Dunkerque, CS 44229, 35042 Rennes Cedex, France.
J Vasc Interv Radiol. 2005 Jun;16(6):841-8. doi: 10.1097/01.RVI.0000156192.89569.0C.
Previous studies have shown that the use of Lipiodol UltraFluid (LUF) emulsified with water leads to an increase in the tumoral uptake of iodine I 131-labeled LUF and reduced pulmonary uptake. Although emulsions containing LUF are currently used for chemoembolization of hepatocellular carcinomas (HCCs), this approach is impossible with intraarterial radiation therapy (RT) because of the problems of radiation protection linked to instability of the emulsions. The aims of this study were to develop stabilized emulsions of radiolabeled LUF of different particle sizes and viscosities and to study its biodistribution in rats with HCC.
An emulsifier made of polyethylene glycol and hydrogenated castor oil was used to stabilize emulsions containing water and technetium Tc 99m-labeled Super Six Sulfur LUF. The various emulsions were injected in the hepatic arteries of rats with HCC. Twenty-four hours after injection, the rats were killed and the liver, tumor, and lungs were removed to perform ex-vivo gamma-counting to quantify tumoral, hepatic, and pulmonary uptake.
Emulsions of oil in water and water in oil of different viscosities (0.68-1.06 Pa.S) and particle size distributions (21-45 mum) were prepared and kept stable for more than 24 hours. Whatever the type of emulsion, the observed effect on tumoral uptake was the opposite of that expected. Indeed, a decrease in tumoral activity was observed (P < .05 in three of five cases) and a tendency toward increased pulmonary activity was observed (P < .05 in two of five cases) rather than any significant decrease.
This study made it possible to develop emulsions of radiolabeled iodized oil that remain stable for more than 24 hours. However, studies of biodistribution in rats with HCC failed to demonstrate any improvement in tumoral targeting, but rather showed a decrease in tumoral uptake that renders this approach impractical for intraarterial radiolabeled iodized oil RT as well as for intraarterial iodized oil chemoembolization. These results may possibly be explained by the use of an emulsifier containing lipophilic and hydrophilic components that modify the properties of LUF.
先前的研究表明,用水乳化的超液化碘油(LUF)可使碘I 131标记的LUF在肿瘤中的摄取增加,并减少肺部摄取。尽管目前含LUF的乳剂用于肝细胞癌(HCC)的化疗栓塞,但由于与乳剂不稳定性相关的辐射防护问题,这种方法在动脉内放射治疗(RT)中无法使用。本研究的目的是开发不同粒径和粘度的放射性标记LUF稳定乳剂,并研究其在HCC大鼠中的生物分布。
使用由聚乙二醇和氢化蓖麻油制成的乳化剂来稳定含有水和锝Tc 99m标记的超六硫化LUF的乳剂。将各种乳剂注入HCC大鼠的肝动脉。注射24小时后,处死大鼠,取出肝脏、肿瘤和肺进行体外γ计数,以量化肿瘤、肝脏和肺部的摄取。
制备了不同粘度(0.68 - 1.06 Pa·S)和粒径分布(21 - 45μm)的水包油型和油包水型乳剂,并保持稳定超过24小时。无论乳剂类型如何,观察到的对肿瘤摄取的影响与预期相反。实际上,观察到肿瘤活性降低(五例中有三例P < 0.05),并且观察到肺部活性有增加的趋势(五例中有两例P < 0.05),而不是任何显著降低。
本研究使得开发放射性标记碘化油乳剂成为可能,该乳剂可保持稳定超过24小时。然而,在HCC大鼠中的生物分布研究未能证明肿瘤靶向有任何改善,反而显示肿瘤摄取减少,这使得这种方法对于动脉内放射性标记碘化油RT以及动脉内碘化油化疗栓塞都不实用。这些结果可能是由于使用了含有亲脂性和亲水性成分的乳化剂,从而改变了LUF的性质。